###### Strengths and limitations of this study

-   The non-invasive measurement of fractional flow reserve (FFR) can improve diagnostic performance for the severity of coronary disease and enhance the quality of patient outcomes.

-   The novel simulating method for predicting FFR in the study allows shorter time and easier access using an on-site personal computer.

-   The study aims to reduce the biases associated with selection and referrals through a multicentre, prospective study design.

-   The study excludes patients with acute myocardial infarction, previous percutaneous coronary intervention or coronary artery bypass graft, so there is a limitation that the generalisation potential of computed FFR for the overall patients with coronary artery disease is unknown.

Introduction {#s1}
============

Fractional flow reserve (FFR) has become the standard of care for functional assessment of the extent and severity of coronary disease.[@R1] Recent advances in CT and computational fluid dynamics (CFD) have enabled estimation of FFR with routine CT angiography acquired at rest. Haemodynamics of the aorta and coronary arteries calculated using CFD are coupled with parameter models of the cardiovascular system. The current technology has shown acceptable diagnostic accuracy compared with invasive FFR.[@R3] However, there are several limitations with it, such as prolonged time for calculation and the need for high-performance computational power; these hamper its widespread use in clinical practice.

Recently, a novel simulating method for predicting FFR with coronary CT angiography (CCTA) has been developed.[@R6] It represents a simple simulation method using a personal computer to estimate FFR values. CT images of coronary arteries and basal physiological data of patients are the only requirements for patient-specific simulation model.[@R6] For the construction of a patient-specific CFD model, a fast segmentation system of CT images is used, which enables the on-site solution of computational FFR (c-FFR). The lumped parameter model used to reflect the effect of microvasculature and veins adopts only the coronary circulation rather than using the entire cardiovascular system ([figures 1 and 2](#F1 F2){ref-type="fig"}). Potential advantages include shorter computational time and no need for supercomputers.

![Process of computational fractional flow reserve (FFR) calculation. (A) Digital imaging and communications in medicine (DICOM) data sets from segmented coronary CT angiography image and physiological data required for haemodynamic calculations. (B) FFR is calculated through computational fluid dynamic (CFD) technique and three-dimensional (3D) vascular modelling. Blood flow is calculated using coronary artery length instead of the volume of myocardium based on lumped parameter model (LPM) resistance. (C) Visualised results are derived based on the computed FFR.](bmjopen-2020-037780f01){#F1}

![An example case of computed and invasive FFR. (A) 3D model reconstruction derived from CCTA image segmentation and FFR simulated using the novel methods. (B) Coronary angiography shows significant stenosis at the proximal LAD, an intermediate lesion at the distal LCX and an insignificant lesion at the mid-RCA. The arrow indicates the position of the pressure sensor when measuring FFR. The measured FFR was 0.79 for LAD, 0.87 for LCX and 0.99 for RCA, respectively. (C) The computed FFR at the corresponding point was 0.77, 0.90 and 0.96. 3D, three-dimensional; CCTA, coronary CT angiogram; FFR, fractional flow reserve; LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery.](bmjopen-2020-037780f02){#F2}

A recent retrospective analysis demonstrated acceptable diagnostic performance of the simulation method.[@R8] In this study, we will prospectively perform a trial to confirm the diagnostic performance of c-FFR. c-FFR estimated using the routine CCTA images will be compared with anatomical assessment alone with invasive FFR as the reference standard.

Methods {#s2}
=======

Study aim {#s2-1}
---------

This study will be a prospective, multicentre, comparative and confirmatory trial. The primary objective of the trial is to assess the diagnostic performance of c-FFR based on routinely acquired CCTA (HeartMedi V.1.0, SiliconSapiens, Korea) in patients with coronary artery disease. The invasive FFR acquired during invasive coronary angiography (ICA) will be the reference standard, and non-invasive CCTA will be the comparator diagnostic method. The primary endpoint is to test the superiority of c-FFR compared with CCTA alone in terms of identification of significant haemodynamic stenosis validated by invasive FFR with ICA.

Study population {#s2-2}
----------------

Patients with coronary artery disease undergoing non-emergent ICA and invasive FFR will be eligible for inclusion in the trial. All study subjects will provide written informed consent. CCTA with ≥64 multidetector slices needs to be taken within 90 days before enrolment. ICA and invasive FFR will be performed with a clinical indication that will be left on physicians' discretion. Patients will be enrolled after completion of ICA and invasive FFR if he/she provides informed consent ([figure 3](#F3){ref-type="fig"}). The key inclusion criteria include the presence of CCTA within 90 days, available ICA and invasive FFR measurements. Key exclusion criteria include resting anginal symptom, chronic kidney disease, tachycardia, hypotension and high coronary artery calcium score. The inclusion and exclusion criteria are detailed in [table 1](#T1){ref-type="table"}. The study subjects will be enrolled from 12 medical centres in Korea.

###### 

Inclusion and exclusion criteria

  Inclusion criteria                                                                                                                                                                                            Exclusion criteria
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Men and women age ≥19Voluntary agreement to a written consent64 Multidetector row CCTA taken within 90 days of coronary angiographySubjects who need a preliminary test for FFR during coronary angiography   Needs for emergency proceduresDifficult cooperating with medical staff for reasons such as cognitive impairmentExperienced acute myocardial infarction within the last 30 daysReport of chest pain during rest (CCS class IV)Impaired chronic renal function (serum creatinine \>2.0 mg/dL)Heart rate ≥100 beats/minSystolic BP ≤90 mm HgCAC ≥1000PregnancyBody mass index \>35 kg/m^2^Prior PCI or CABG in the subject blood vesselPrevious valvular surgeryComplicated congenital heart diseaseAcute pulmonary oedemaUnstable haemodynamics including cardiogenic shock, abrupt chest painPacemaker or internal defibrillator leads implantedKnown hypersensitivity or contraindication to β-blocker, nitroglycerin, adenosineHistory of contrast dye allergySignificant arrhythmia including complete AV block, ventricular arrhythmiaSubjects who are currently participating in other clinical trials or have participated in other clinical trials within 30 days before screeningOthers who are inappropriate subject judged by clinician

AV, atrioventricular; BP, blood pressure; CABG, coronary artery bypass graft; CAC, coronary artery calcium; CCS, Canadian Cardiovascular Society; CCTA, coronary CT angiography; FFR, fractional flow reserve; PCI, Percutaneous coronary intervention.

![Study flow. CCTA, coronary CT angiography; FFR, fractional flow reserve.](bmjopen-2020-037780f03){#F3}

Study process {#s2-3}
-------------

Study images such as CCTA, ICA and invasive FFR will be transferred to blinded independent core laboratories where study images of CCTA and invasive FFR will be interpreted independently. CCTA images will be anonymised and sent to the vendor (c-FFR core laboratory), where measurements of c-FFR will be performed. All study processes will be blinded, and measurements will be conducted independently. All measurement data will be recorded in electronic case report forms, which will be blinded to other participants of the study. Specifically, the c-FFR core laboratory of SiliconSapiens will be completely blinded to the findings of the CCTA, quantitative coronary angiography and invasive FFR core laboratories. The independent statistical core laboratory will collect the data after completion of the trial.

Coronary CT angiography {#s2-4}
-----------------------

Patients who underwent CCTA as part of routine clinical care will be enrolled in the study. The minimum requirement for CCTA includes ≥64 multidetector slices and a row width of ≤0.75 mm. CT angiography scanning protocols in the participating centres are consistent with the quality standards by the Society of Cardiac Computed Tomography.[@R9] The quality of CCTA images of each participating centre has been confirmed by the core laboratory before the trial initiation. Study CCTA images will be transmitted to the core laboratory, where the characteristics and severity of coronary atherosclerotic lesions will be quantified by two independent, blinded radiologists. Any disagreement between the two radiologists will be resolved by discussion. The coronary system will be divided into the left anterior descending artery, left circumflex artery and right coronary artery (RCA) and then further into 15 segments according to the American Heart Association (AHA) classification guidelines.[@R10] Using a semiautomated dedicated three-dimensional workstation (Intellispace Portal, Philips Healthcare, Cleveland, Ohio, USA), curved multiplanar reformatted images will be reconstructed for assessment. The degree of stenosis of the vessels will be measured around the narrowest area at a rate based on the average of the normal coronary arteries above and below the stenosis site. Quantitative analysis of stenosis grade will be classified as normal (0%), minimal (1%--24%), mild (26%--49%), moderate (50%--69%), severe (70%--99%) and occlusion (100%) according to Society of Cardiovascular Computed Tomography guidelines.[@R9]

Coronary angiography {#s2-5}
--------------------

ICA and invasive FFR procedures will be performed according to the American College of Cardiology/AHA for guidelines for coronary angiography and intervention.[@R12] Intracoronary nitroglycerine (100--200 mg) will be administered in the coronary arteries before initial cine angiograms unless contraindicated. Coronary arterial images will be obtained with selective catheterisation of the left coronary artery and RCA. The coronary angiography images will be analysed using an automated edge-detection system (Cardiovascular Angiography Analysis Systems, Maastricht, the Netherlands) at the core laboratory by an experienced technician who is blinded to the study. After calibration with the outer diameter of the coronary catheter, the minimal lumen diameter, reference vessel diameter, % diameter stenosis, will be measured. If there are two or more stenosed vessels over 2.0 mm, the most severe lesion will be chosen as the index lesion.

Invasive FFR {#s2-6}
------------

The invasive FFR measurements performed in the coronary arteries with a diameter of ≥2 mm will be included in the study. The invasive FFR should be measured using a sensor-tipped 0.014-inch guidewire (PressureWire; St. Jude Medical, St. Paul, Minnesota, USA or Verrata Wire; Philips, Eindhoven, the Netherlands) through a 5--7 Fr guiding catheter. Pressure calibration should be confirmed as zero at the ascending aorta or proximal segment of the coronary arteries. The location of the pressure wire distal to the index lesion should be recorded on a coronary angiographic image. Maximal myocardial hyperaemia should be induced by continuous intravenous adenosine infusion via a central or peripheral vein with an infusion rate of 140 mg/kg/min. The invasive FFR will be calculated as the mean distal coronary pressure divided by the mean aortic pressure during hyperaemia. A pullback recording should be performed and recorded. The absence of pressure signal drift (0.97‒1.03) needs to be confirmed at the distal end of the guiding catheter. The raw data of the invasive FFR measurements will be sent to the invasive FFR core laboratory, where potential bias such as maximum hyperaemia and pressure drift will be confirmed, and the measurements will be validated. The validated invasive FFR values will be transmitted to the statistical core laboratory.

Computational FFR {#s2-7}
-----------------

The vendor (c-FFR core laboratory) will receive the segmented CCTA images from the CCTA core laboratory. The invasive FFR core laboratory will demarcate the location of invasive FFR measurement on the reconstructed CCTA, which will be transmitted to SiliconSapiens via the study coordinator. SiliconSapiens will analyse c-FFR according to the method of using medical devices for clinical trials. The simulations use a three-dimensional model of epicardial coronary arteries derived from CCTA image segmentation, and the estimation is based on vessel lengths but not on myocardial volume. The parameters will be assigned by physiological data customised to each individual patient-specific model. Coronary blood flow will be simulated under conditions that mimic maximal hyperaemia. For suboccluded or chronically occluded arteries by CCTA (ie, stenosis \>90%), default c-FFR values of 0.50 will be assigned to that vessel.

Primary efficacy analysis {#s2-8}
-------------------------

The primary measure of performance will be the area under the receiver--operator characteristic curve (AUC) to detect haemodynamically significant stenosis. The gold standard for significant stenosis will be defined as invasive FFR ≤0.80. The measurements will be % stenosis for CCTA and simulated FFR based on CT for c-FFR. Sensitivity will be plotted against (1−specificity) for different cut-off points of the study measurements. The AUC, SE and 95% CIs will be presented. Delong's test will be used to compare two correlated C-statistics.[@R13]

Secondary efficacy analysis {#s2-9}
---------------------------

Diagnostic accuracy, sensitivity, specificity, positive [predictive value](https://www.sciencedirect.com/topics/medicine-and-dentistry/predictive-value-of-tests) (PPV), negative predictive value (NPV) and correlation will be presented as secondary analyses. The cut-off for significant obstruction of CCTA will be defined as a diameter stenosis of ≥50%. The cut-off for c-FFR will the simulated c-FFR measured by the software HeartMedi V.1.0 of ≤0.8. Each value will be calculated as shown below.

$$Predictiveaccuracy = \frac{TP + TN}{TP + FP + FN + TN}$$

$$Sensitivity = \frac{TP}{TP + FN}$$

$$Specificity = \frac{TN}{TN + FP}$$

$$Positivepredictivevalue = \frac{TP}{TP + FP}$$

$$Negativepredictivevalue = \frac{TN}{TN + FN}$$

(TP, True positive; TN, True negative; FP, False positive; FN, False negative.)

Each value and 95% CI will be presented. The performance will be compared using McNemar's test. Correlation will be assessed with the use of Pearson or Spearman Correlation, whereby coefficient (r) and p values will be determined.

Statistical hypotheses and sample size calculation {#s2-10}
--------------------------------------------------

The study hypothesis is that the AUC of c-FFR would be greater than that of CCTA. The NXT (HeartFlow analysis of coronary blood flow using CT angiography: NeXt sTeps) trial previously reported the AUC of FFR~CT~ (HeartFlow) and CCTA to be 0.90 and 0.81, respectively.[@R3] The NOVEL-FLOW (Diagnostic Performance of a Novel Method for Fractional Flow Reserve Computed From Noninvasive Computed Tomography Angiography) study also showed similar discriminatory functions (AUC, 0.93 for CT-FFR and 0.74 for CCTA).[@R8] In the present study, the AUC of c-FFR and CCTA was assumed to be 0.90 and 0.81, respectively. We expected the prevalence of haemodynamically significant stenosis to be 31.5% based on the previous studies.[@R3] The assumptions included 0.6 of the correlation coefficient of AUCs between c-FFR and CCTA and the attrition rate of 15%. With these assumptions, 184 study participants would be required to achieve a one-sided significance level of 0.025 and power of 80%.

Patient and public involvement {#s2-11}
------------------------------

There was no patient or public involvement in the design of the present study, and there is no planned patient or public involvement to recruit and conduct the study.

Discussion {#s3}
==========

FFR-guided coronary revascularisation has shown clinical benefits over angiography guidance alone.[@R18] CCTA is currently the most widely used imaging modality for non-invasive coronary evaluation.[@R20] Recent advances in CT imaging enabled high diagnostic accuracy for detecting obstructive coronary artery disease.[@R22] The combination of high image quality of CCTA and functional assessment of FFR has the potential to improve diagnostic performance and enhance the quality of patient outcomes. It allows the functional assessment of coronary stenosis without invasive catheterisation, which inevitably is associated with complications.

Previous studies have proven the benefit of such approaches, including FFR~CT~ developed by HeartFlow.[@R24] The limitations of this technology include the need for high-performance computing power, long computation time and potential simulation errors. The novel simulation method tested in this study (CT-FFR, HeartMedi V.1.0) has several advantages over the previous methods. The previous methods use CFD that requires myocardial mass estimation based on the whole cardiac anatomy coupled with lumped parameter models (volume-based method).[@R3] In contrast, CFD used in the novel c-FFR technology calculates vessel length and three-dimensional coronary artery geometry, which is combined with coronary circulation of lumped parameter models (length-based method). A previous study demonstrated no significant difference in haemodynamic simulation between the two estimation methods.[@R7] The feature is translated into less need for computational power. Functional assessment can be performed on-site with a personal computer environment without transferring large volume CT images to central laboratories. In addition, this method excludes the possibility of errors due to the segmentation of left ventricular muscle.

One previous study retrospectively analysed 218 vessels from 117 patients to validate the c-FFR method compared with invasively measured FFR.[@R8] The accuracy, sensitivity, specificity, PPV and NPV of c-FFR were shown to be 85.8%, 86.2%, 85.5%, 79.8% and 90.3%, respectively. The diagnostic performance measured by the AUC was significantly higher for c-FFR than those for CCTA. c-FFR showed a slight underestimation of the functional severity of the lesions. The present study is designed to prospectively validate the performance of the novel simulation method. Eligible subjects who have coronary artery disease with CCTA and invasive FFR available will be prospectively enrolled. The sample size is planned based on the statistical power calculation.

In conclusion, the present study will prospectively assess the diagnostic performance of c-FFR. The values will be compared with that of CCTA with invasive FFR as the gold standard.

Limitations {#s3-1}
-----------

Since this study excludes patients with acute myocardial infarction, previous percutaneous coronary intervention or coronary artery bypass graft, there is a limitation that the generalisation potential of computed FFR for the overall patients with coronary artery disease is unknown. However, the novel method in this study can be easily applied to these cases, and further study will attempt to include them.

Another limitation of the present study is that, although prospective, we are recruiting patients following the performance of CCTA and invasive FFR. This may lead to selection bias. Finally, while the technology was developed for on-site usage, the measurements will be performed in a core laboratory. This was included in the study design to ensure adequate blinding of investigators to the reference values and hence to minimise the study bias.

Protocol amendments {#s3-2}
-------------------

All changes in the study protocol were reviewed by the ethics committee of Seoul National University Bundang Hospital and reported to the sponsor and funder. Significant protocol changes were recorded in Clinical Research Information Service.

Ethics and dissemination {#s3-3}
------------------------

This study was approved by the institutional review board of Seoul National University Bundang Hospital (E-1709/420-001). Written informed consent will be obtained for all enrolled patients. The result will be published in a peer-reviewed journal.

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

So-HK and Si-HK contributed equally.

**Contributors:** Si-HK and T-JY conceived and designed the study. So-HK and Si-HK wrote the draft of the paper. W-YC, C-HY, S-DP, C-WN, K-HK, J-HD, Y-SB and J-WB will conduct screening and data collection. Analysis will be performed by Si-HK, So-HK and T-JY. T-JY and I-HC were involved in critical revision of the study for important intellectual content. All authors contributed to revision and approved the final version of the manuscript.

**Funding:** This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI17C2006). The sponsor, SiliconSapiens, due to the nature of the study, will only provide data that independently analyse computational FFR. The protocol design or the implementation, management, data collection and analysis of the study is entirely independent of the vendor company (SiliconSapiens) or funder.

**Competing interests:** None declared.

**Patient and public involvement:** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication:** Not required.

**Provenance and peer review:** Not commissioned; externally peer reviewed.
